AQP4 NMOSDMS;

Yongkang Chen1, Yilin Wang2, Ruoqi Jin2

  • 1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China; Institute of Parkinson and Movement Disorder, Zhengzhou University, Zhengzhou, Henan 450052, China; Academy of Medical Sciences of Zhengzhou University, Zhengzhou, Henan 450000, China.

PubMed
概括

通过估计的膜过率 (eGFR) 测量功能,与水素-4 (AQP4) 免疫球蛋白G (IgG) 血清阳性神经omyelitis optica谱系障碍 (NMOSD) 的复发风险有关. 更高的eGFR预测了更好的预后和更低的复发风险.